Clinical studies have reported that mutations in ARHGEF18 lead to increased susceptibility to nonidiopathic pulmonary hypertension associated with coronary artery disease (Li et al., 2018), and systematic knockdown of Arhgef18 results in embryonic death in mice (Beal et al., 2021). Here, ARHGEF18 is linked to pulmonary hypertension.